CN Patent

CN110845476B — 一种高选择性csf1r抑制剂、其制备方法和在药学上的应用

Assigned to Abbisko Therapeutics Co Ltd · Expires 2022-11-18 · 3y expired

What this patent protects

本发明涉及一种具有式(I)结构的高选择性CSF1R抑制剂、其制备方法和在药学上的应用。本发明化合物可广泛应用于制备治疗癌症、肿瘤、自身免疫性疾病、代谢性疾病或转移性疾病的药物，特别是治疗卵巢癌、胰腺癌、前列腺癌、乳腺癌、宫颈癌、成胶质细胞瘤、多发性骨髓瘤、代谢性疾病、神经变性疾病、原发性肿瘤位点的转移或骨转移性癌症的药物，有望开发成新一代CSF1R抑制剂药物。

USPTO Abstract

本发明涉及一种具有式(I)结构的高选择性CSF1R抑制剂、其制备方法和在药学上的应用。本发明化合物可广泛应用于制备治疗癌症、肿瘤、自身免疫性疾病、代谢性疾病或转移性疾病的药物，特别是治疗卵巢癌、胰腺癌、前列腺癌、乳腺癌、宫颈癌、成胶质细胞瘤、多发性骨髓瘤、代谢性疾病、神经变性疾病、原发性肿瘤位点的转移或骨转移性癌症的药物，有望开发成新一代CSF1R抑制剂药物。

Drugs covered by this patent

pexidartinib-hydrochloride (PEXIDARTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN110845476B
Jurisdiction: CN
Classification: —
Expires: 2022-11-18
Drug substance claim: No
Drug product claim: No
Assignee: Abbisko Therapeutics Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.